|
2017 |
BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells |
Cuyàs, Elisabet
; Corominas Faja, Bruna
; Muñoz-San Martín, María
; Martin Castillo, Begoña
; Lupu, Ruth
; Brunet i Vidal, Joan
; Bosch Barrera, Joaquim
; Menéndez Menéndez, Javier Abel
|
|
|
BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells |
Cuyàs, Elisabet
; Corominas Faja, Bruna
; Muñoz-San Martín, María
; Martin Castillo, Begoña
; Lupu, Ruth
; Brunet i Vidal, Joan
; Bosch Barrera, Joaquim
; Menéndez Menéndez, Javier Abel
|
|
|
|
BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells |
Cuyàs, Elisabet
; Corominas Faja, Bruna
; Muñoz-San Martín, María
; Martin Castillo, Begoña
; Lupu, Ruth
; Brunet i Vidal, Joan
; Bosch Barrera, Joaquim
; Menéndez Menéndez, Javier Abel
|
|
|
5 juny 2018 |
BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells |
Cuyàs, Elisabet
; Corominas Faja, Bruna
; Muñoz-San Martín, María
; Martin Castillo, Begoña
; Lupu, Ruth
; Brunet i Vidal, Joan
; Bosch Barrera, Joaquim
; Menéndez Menéndez, Javier Abel
|
|
|
|
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez Martín, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz, Rosa
; Cufí González, Sílvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez Martínez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
|
|
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez Martín, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz, Rosa
; Cufí González, Sílvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez Martínez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
|
5 juny 2018 |
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez Martín, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz, Rosa
; Cufí González, Sílvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez Martínez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
|
2011 |
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez Martín, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz Duran, Maria Rosa
; Cufí González, Sílvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez Martínez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
|
abril 2012 |
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts |
Cufí González, Sílvia
; Corominas Faja, Bruna
; Vázquez Martín, Alejandro
; Oliveras Ferrarós, Cristina
; Dorca Ribugent, Joan
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Menéndez Menéndez, Javier Abel
|
|
|
|
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts |
Cufí González, Sílvia
; Corominas Faja, Bruna
; Vázquez Martín, Alejandro
; Oliveras Ferrarós, Cristina
; Dorca Ribugent, Joan
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Menéndez Menéndez, Javier Abel
|
|
|
|
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts |
Cufí González, Sílvia
; Corominas Faja, Bruna
; Vázquez Martín, Alejandro
; Oliveras Ferrarós, Cristina
; Dorca Ribugent, Joan
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Menéndez Menéndez, Javier Abel
|
|
|
5 juny 2018 |
Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts |
Cufí González, Sílvia
; Corominas Faja, Bruna
; Vázquez Martín, Alejandro
; Oliveras Ferrarós, Cristina
; Dorca Ribugent, Joan
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Menéndez Menéndez, Javier Abel
|
|
|
2014 |
Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment |
Menéndez Menéndez, Javier Abel
; Quirantes Piné, Rosa
; Rodríguez Gallego, Esther
; Cufí González, Sílvia
; Corominas Faja, Bruna
; Cuyàs, Elisabet
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Segura Carretero, Antonio
; Joven, Jorge
|
|
|
|
Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment |
Menéndez Menéndez, Javier Abel
; Quirantes Piné, Rosa
; Rodríguez Gallego, Esther
; Cufí González, Sílvia
; Corominas Faja, Bruna
; Cuyàs, Elisabet
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Segura Carretero, Antonio
; Joven, Jorge
|
|
|
|
Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment |
Menéndez Menéndez, Javier Abel
; Quirantes Piné, Rosa
; Rodríguez Gallego, Esther
; Cufí González, Sílvia
; Corominas Faja, Bruna
; Cuyàs, Elisabet
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Segura Carretero, Antonio
; Joven, Jorge
|
|
|
5 juny 2018 |
Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment |
Menéndez Menéndez, Javier Abel
; Quirantes Piné, Rosa
; Rodríguez Gallego, Esther
; Cufí González, Sílvia
; Corominas Faja, Bruna
; Cuyàs, Elisabet
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Segura Carretero, Antonio
; Joven, Jorge
|
|
|
|
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype |
Cuyàs, Elisabet
; Fernández Arroyo, Salvador
; Corominas Faja, Bruna
; Rodríguez Gallego, Esther
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Llorens Duran, Rafael de
; Joven, Jorge
; Menéndez Menéndez, Javier Abel
|
|
|
|
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype |
Cuyàs, Elisabet
; Fernández Arroyo, Salvador
; Corominas Faja, Bruna
; Rodríguez Gallego, Esther
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Llorens Duran, Rafael de
; Joven, Jorge
; Menéndez Menéndez, Javier Abel
|
|
|
5 juny 2018 |
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype |
Cuyàs, Elisabet
; Fernández Arroyo, Salvador
; Corominas Faja, Bruna
; Rodríguez Gallego, Esther
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Llorens Duran, Rafael de
; Joven, Jorge
; Menéndez Menéndez, Javier Abel
|
|
|
20 maig 2015 |
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype |
Cuyàs, Elisabet
; Fernández Arroyo, Salvador
; Corominas Faja, Bruna
; Rodríguez Gallego, Esther
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Llorens Duran, Rafael de
; Joven, Jorge
; Menéndez Menéndez, Javier Abel
|
|
|
15 febrer 2020 |
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype |
Cuyàs, Elisabet
; Fernández Arroyo, Salvador
; Corominas Faja, Bruna
; Rodríguez Gallego, Esther
; Bosch Barrera, Joaquim
; Martin Castillo, Begoña
; Llorens Duran, Rafael de
; Joven, Jorge
; Menéndez Menéndez, Javier Abel
|
|
|
12 setembre 2016 |
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer |
Queralt, Bernardo
; Cuyàs, Elisabet
; Bosch Barrera, Joaquim
; Massaguer i Vall-llovera, Anna
; Llorens Duran, Rafael de
; Martin Castillo, Begoña
; Brunet i Vidal, Joan
; Salazar, Ramon
; Menéndez Menéndez, Javier Abel
|
|
|
|
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer |
Queralt, Bernardo
; Cuyàs, Elisabet
; Bosch Barrera, Joaquim
; Massaguer i Vall-llovera, Anna
; Llorens Duran, Rafael de
; Martin Castillo, Begoña
; Brunet i Vidal, Joan
; Salazar, Ramon
; Menéndez Menéndez, Javier Abel
|
|
|
|
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer |
Queralt, Bernardo
; Cuyàs, Elisabet
; Bosch Barrera, Joaquim
; Massaguer i Vall-llovera, Anna
; Llorens Duran, Rafael de
; Martin Castillo, Begoña
; Brunet i Vidal, Joan
; Salazar, Ramon
; Menéndez Menéndez, Javier Abel
|
|
|
5 juny 2018 |
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer |
Queralt, Bernardo
; Cuyàs, Elisabet
; Bosch Barrera, Joaquim
; Massaguer i Vall-llovera, Anna
; Llorens Duran, Rafael de
; Martin Castillo, Begoña
; Brunet i Vidal, Joan
; Salazar, Ramon
; Menéndez Menéndez, Javier Abel
|
